Larry Profile picture
31 Oct, 13 tweets, 7 min read
#ncyt #alnov

Thread :

Acquisition of IT-IS International Ltd by #novacyt

Everybody knows now that #ncyt has buyed it-is, developer of the MyGo Pro (Q32) and MyGo Mini (q16) among other patented instruments and products.

1/12
We also all know the contract #ncyt just signed with the UK DHSC for the supply, in a first phase, of 300 Q32, and a possible second phase of 700 of those instruments.

We are also selling Q16 and Q32 through our distributors worldwide.

2/12
It-is is not just those two instruments.
It's also technologies :

- multichannel spectrometer
- data analysis algorithms
- graphical user interfaces
- pcr analysis algorithms
- mass spectrometry analysis
- Thermaxis® technology
- etc

Read more : itisint.com

3/12
In the picture, you can see a 2017 order
For 100 q16 for China.
This was big at the time...

Find here part of the various patents from it-is :

worldwide.espacenet.com/searchResults?…

4/12
#ncyt's Genesig covid tests are compatible with the instruments.

But not only our test does. At least three other tests being used around the world have the MyGo on their IFU.

Wich means point of Care testing can be achieved in several countrys with our instruments.

5/12
First test being noticed by all the great reasearchers of #ncyt is the FRANKD RT-LAMP by GeneMe.

We saw it being trialed at Heatrow airport and they were using the Q32.
And like @nolfa77 said in his thread earlier, it has been accepted by Hong Kong for air travellers.

6/12
Second test validated for use with MyGo (among others) is the first covid test made by a Czech compagny : Eligene.

This test is avaiable in a number of european countrys at least (Romania, hungary, belgium, spain, Czech rep.,...)

7/12
Third and last test i found is from a Korean compagny : KH Medical.

The Radi covid-19 kit wich has also CE mark.
It works with the Radi PCR system wich is in fact our q16 under oem agreement.

See the nice advertising in the photo.

8/12
This is only one of our OEMs for the MyGo instruments.

Hygiena, with his BAX System X5 is another example of success of OEM sells.

9/12
In conclusion,

- The acquisition make the ramping of the production possible to answer the growing demand there is in this covid crisis.

- Our distributors and the ones of IT-IS give us a worldwide range.

- The various tests working with MyGo will enhance those sells.

10/12
- the reputation of #ncyt will increase and allow G. Mullis to create a leader in IVD-diagnostics.

- The Q16/32 will stay after covid, and the NHS or others will continue to buy the tests, reagents and other products from the compagny that helped them during covid.

11/12
This acquisition will allow us to :

- Develop our POC testing like the NPT
- Develop airport testing
- Allow decentralized testing everywhere

With or without our tests with it, this acquisition is a real asset for the compagny, and a good money maker with good margins.

12/12
Thanks to all the novacyt researchers that helped to do this thread. 👏👏👏

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Larry

Larry Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!